



AROA BIOSURGERY QUARTERLY RESULTS WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on **Wednesday 29 January, at 9 AM AEDT**, to discuss the December Quarterly Results which will be released pre-market on the same day.

Following presentation of the Quarterly Results, Dr. Brandon Bosque and Dr. John Lawlor will discuss the findings of the Company's most recently published clinical study, *Limb Salvage via Surgical Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A prospective study*.

Investors and interested parties can register to attend the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_MrYng6hPQhK0MP7HW2CJ5g

Questions can be submitted before the webinar to investor@aroa.com or during the webinar using the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com

Contacts

investor@aroabio.com